NCT01351909 - Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2011

Primary Completion Date

November 25, 2016

Study Completion Date

March 18, 2026

Conditions

Locally Advanced Unresectable Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG

Cyclophosphamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Veliparib

Given PO

Trial Locations (5)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

10461

Montefiore Medical Center-Einstein Campus, The Bronx

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH